Yorvipath denied as non-formulary by Humana?

Humana's specific coverage criteria for yorvipath are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied Yorvipath as Non-Formulary — and Your Path to Coverage

A non-formulary denial means Yorvipath (palopegteriparatide) is not on the tier of Humana's drug formulary that your plan covers, or is excluded from the formulary entirely. This is one of the most common denial types and, importantly, one of the most straightforward to appeal through the formulary exception process — a pathway that exists precisely for situations where a non-formulary drug is medically necessary for a specific patient.

## Why This Is Appealable

Federal law and Humana's own plan documents require that a formulary exception process be available whenever a formulary drug is contraindicated, inadequate, or clinically inappropriate for the patient. For Yorvipath — a hormone-replacement therapy for a specific endocrine deficiency — the argument is that the formulary alternatives either are not therapeutically equivalent (because they treat symptoms rather than replacing the missing hormone) or have been tried and found inadequate for this patient. The formulary exception process is separate from, and in addition to, the standard internal/external appeal process.

## Federal Appeal Framework

• Formulary exception request: Submit a physician-supported exception request to Humana before or alongside the formal internal appeal. This is a distinct process and often faster.
• Internal appeal (ACA §2719 / ERISA §503): A formal internal appeal of the non-formulary denial runs concurrently. Submit within the deadline on the denial letter.
• External review (ACA §2719): Non-formulary denials that are grounded in medical-necessity reasoning are eligible for IRO review. The external review window is typically up to four months. IRO decisions are binding.
• Expedited review: Available if the condition is urgent; the insurer must respond within days rather than weeks.

## Documentation to Gather

1. Formulary alternative review — obtain Humana's current formulary and identify every listed alternative for hypoparathyroidism management. The prescriber must address each alternative and explain why it is clinically inadequate, contraindicated, or has already been tried and failed. 2. Prior-treatment history — dated records of every conventional therapy attempted, the duration, the clinical response (or lack thereof), and any adverse effects. 3. Diagnosis confirmation — laboratory and clinical documentation confirming the hypoparathyroidism diagnosis, etiology, and severity. 4. Prescriber exception letter — the treating endocrinologist should specifically request a formulary exception, explain why each formulary alternative is not appropriate for this patient, and assert that Yorvipath is medically necessary. 5. FDA approval and indication — confirm in writing that Yorvipath is FDA-approved for the patient's specific diagnosis.

## Criteria-Mapping Strategy

Humana's formulary exception criteria typically require documentation that formulary alternatives are contraindicated, have been tried and failed, or are otherwise clinically inappropriate. Build the appeal around each of those prongs. For any alternative the prescriber has not yet tried, explain the clinical reason it was bypassed. A well-documented formulary exception appeal that addresses every listed alternative individually is the most effective format for this denial type.